NeuroDerm Company Profile (NASDAQ:NDRM)

Analyst Ratings

Consensus Ratings for NeuroDerm (NASDAQ:NDRM) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $26.88 (53.48% upside)

Analysts' Ratings History for NeuroDerm (NASDAQ:NDRM)
Show:
DateFirmActionRatingPrice TargetActions
5/29/2016Roth CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/2/2016Oppenheimer Holdings Inc.Initiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/10/2015Raymond James Financial Inc.Initiated CoverageOutperform$28.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/14/2015Jefferies GroupReiterated RatingBuy$28.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/9/2014Cowen and CompanyInitiated CoverageOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/24/2014 forward)

Earnings

Earnings History for NeuroDerm (NASDAQ:NDRM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/26/2016Q1($0.35)($0.25)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/31/2016Q4($0.29)$0.31ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/11/2015Q315($0.34)($0.49)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.20)($0.34)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/27/2015Q115($0.28)($0.09)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/2/2015($0.35)($2.55)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for NeuroDerm (NASDAQ:NDRM)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.29)($0.29)($0.29)
Q2 20162($0.40)($0.34)($0.37)
Q3 20162($0.40)($0.36)($0.38)
Q4 20161($0.37)($0.37)($0.37)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for NeuroDerm (NASDAQ:NDRM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for NeuroDerm (NASDAQ:NDRM)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for NeuroDerm (NASDAQ:NDRM)
DateHeadline
07/23/16 09:17 AMEquity Roundup: Stock Performance Focus on NeuroDerm Ltd. (NASDAQ:NDRM) - Press Telegraph
07/21/16 05:42 PMNeuroderm Limited Ord (NASDAQ:NDRM) Short Interest Decreased By 0.85% - Consumer Eagle
07/21/16 05:42 PMInvestor Update: Earnings and Target Price Recap on NeuroDerm Ltd. (NASDAQ:NDRM) - Press Telegraph
07/18/16 05:32 PMNeuroDerm Ltd. (NASDAQ:NDRM) Wall Street Analyst Recommendation Outlook - TGP
07/18/16 10:44 AMNeuroderm Ltd Formed a Bullish Inverse H&S Pattern, Could Be One of The Best Performers Soon - Press Telegraph
07/15/16 10:13 AMNeuroDerm Ltd. Stock Momentum at Critical Inflection Point - CML News
07/15/16 10:13 AMNeuroDerm Ltd. (NASDAQ:NDRM) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/12/16 05:40 PMHow Many Neuroderm Ltd (NASDAQ:NDRM)'s Analysts Are Bearish? - Consumer Eagle
07/11/16 10:02 AMWall Street Ratings and Target Price Views on NeuroDerm Ltd. (NASDAQ:NDRM) - Telanagana Press
07/07/16 05:26 PMNeuroDerm (NDRM) Names Tami Yardeni as COO - StreetInsider.com
07/07/16 05:26 PMCan NeuroDerm Ltd. (NASDAQ:NDRM) Improve on the Earnings Front? - Engelwood Daily
07/06/16 05:38 PMNeuroDerm (NDRM) Names Tami Yardeni as COO
07/06/16 10:03 AMNeuroDerm Announces Additions to Management Team - [GlobeNewswire] - REHOVOT, Israel, July 06, 2016-- NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system disorders, today announced the appointments of Tami Yardeni as Chief ...
07/05/16 08:05 AMNeuroDerm to Present at the Cantor Fitzgerald Healthcare Conference on July 13 - [GlobeNewswire] - REHOVOT, Israel, July 05, 2016-- NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system diseases, today announced that Oded S. Lieberman, PhD, CEO will present ...
07/04/16 04:44 PMAre Analysts Bearish Neuroderm Ltd (NASDAQ:NDRM) After Last Week? - Press Telegraph
07/01/16 08:14 AMIt's A Ten For Humira, AMPE Drubbed By PIVOT Data, CYNA Awaits Data In Q3
06/30/16 03:03 PMNeuroDerm Announces Start of U.S. Patient Enrollment in Trial 006, a Phase II Trial of ND0612H for Advanced Parkinson’s Disease - [GlobeNewswire] - REHOVOT, Israel, June 30, 2016-- NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system disorders, today announced the start of patient enrollment in the United ...
06/28/16 10:16 AMNeuroDerm Announces ND0612H Achieves Comparable Pharmacokinetics to DUODOPA® in Head-To-Head Pilot PK Comparison Trial
06/27/16 05:18 PMNext Weeks Broker Price Targets For NeuroDerm Ltd. (NDRM) - Fiscal Standard
06/25/16 04:58 PMBrokers Issue Average Price Target Of 27.50 On NeuroDerm Ltd. (NDRM) - Fiscal Standard
06/25/16 04:58 PMNew Broker Ratings For NeuroDerm Ltd. (NDRM) - FTSE News
06/24/16 05:35 PMNeuroDerm Added to Russell Global Index - [GlobeNewswire] - REHOVOT, Israel, June 24, 2016-- NeuroDerm Ltd., a clinical-stage pharmaceutical company developing drugs for central nervous system diseases, today announced that the company has been selected to join ...
06/23/16 05:54 PMNeuroDerm Ltd. (NasdaqGM:NDRM) Stock Momentum at Critical Inflection Point - CML News
06/23/16 08:15 AMNeuroDerm Presents Three Posters at the 20th International Congress of Parkinson’s Disease and Movement Disorders - [GlobeNewswire] - REHOVOT, Israel, June 23, 2016-- NeuroDerm Ltd., a clinical-stage pharmaceutical company developing drugs for central nervous system diseases, today presented pre-clinical data investigating ND0701, its ...
06/20/16 07:02 AMThis Weeks Broker Views For NeuroDerm Ltd. (NDRM) - Fiscal Standard
06/16/16 09:39 AMNeuroDerm to Present Design of the First Clinical Efficacy Study of ND0612H and Other Clinical Data at the 20th International Congress of…
06/16/16 09:39 AMNeuroDerm to present trial data at Parkinson’s conference
06/16/16 09:39 AMNeuroDerm to Present Design of the First Clinical Efficacy Study of ND0612H and Other Clinical Data
06/16/16 06:00 AMNeuroDerm to Present Design of the First Clinical Efficacy Study of ND0612H and Other Clinical Data at the 20th International Congress of Parkinson’s Disease and Movement Disorders - [GlobeNewswire] - -Clinical Trial Evaluating Efficacy, Safety, Tolerability and Pharmacokinetics of Two Dosing Regimens of ND0612 Compared With Oral Standard of Care Treatment in Patients With Advanced Parkinson’ s Disease-. ...
06/08/16 05:49 PMNEURODERM LTD. (NASDAQ:NDRM) Financial Condition Compared to S&P 500 - CML News
06/07/16 08:03 AMNeuroDerm (NDRM) Looks Good: Stock Adds 5.1% in Session
06/03/16 08:14 AMRevenue Update on Neuroderm Ltd(NASDAQ:NDRM) - Trade Calls - Revenue Update on Neuroderm Ltd(NASDAQ:NDRM)Trade CallsNeuroderm Ltd(NASDAQ:NDRM) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during Pre-market on May 26, 2016. Earnings per share were $-0.25. Analysts had estimated an EPS of $-0.35. Neuroderm Ltd (NDRM) ...Stock Review and Earnings Check on NeuroDerm Ltd. (NASDAQ:NDRM)HNNNeuroDerm Ltd. (NASDAQ:NDRM) Stock Update & EstimatesStock Tick Tockall 4 news articles »
06/02/16 05:46 PMNeuroDerm Ltd. (NASDAQ:NDRM) Stock Update & Estimates - Stock Tick Tock - NeuroDerm Ltd. (NASDAQ:NDRM) Stock Update & EstimatesStock Tick TockThe consensus on Wall Street is expecting NeuroDerm Ltd. (NASDAQ:NDRM) to post earnings of $-0.34 per share when the firm next reports it's fiscal quarterly results. According to the latest information available the report will likely be issued around ...and more »
06/02/16 05:46 PMStock Review and Earnings Check on NeuroDerm Ltd. (NASDAQ:NDRM) - HNN - Stock Review and Earnings Check on NeuroDerm Ltd. (NASDAQ:NDRM)HNNInvestors and analysts are typically super focused on company earnings numbers when they are reported. Company earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting NeuroDerm Ltd. (NASDAQ:NDRM) ...and more »
06/02/16 05:46 PMBroker Watchlist: NeuroDerm Ltd. (NDRM) - Share Trading News - Broker Watchlist: NeuroDerm Ltd. (NDRM)Share Trading News12/10/2014 – Cowen began new coverage on NeuroDerm Ltd. giving the company a “outperform” rating. They now have a USD 30 price target on the stock. The share price of NeuroDerm Ltd. (NDRM) was down -0.86% during the last trading session, with a ...
06/02/16 11:59 AMNeuroDerm Ltd. :NDRM-US: Earnings Analysis: Q1, 2016 By the Numbers : June 2, 2016 -
05/31/16 01:11 PMNeuroDerm CEO to Present at Jefferies 2016 Healthcare Conference on June 7 - [GlobeNewswire] - REHOVOT, Israel, May 31, 2016-- NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system diseases, today announced that CEO Oded S. Lieberman, PhD will present ...
05/31/16 09:24 AMShare Rating Focus on NeuroDerm Ltd. (NASDAQ:NDRM) - HNN - Share Rating Focus on NeuroDerm Ltd. (NASDAQ:NDRM)HNNPresently, Wall Street analysts have given a consensus stock rating of 1.2 on shares of NeuroDerm Ltd. (NASDAQ:NDRM). Covering analysts will typically provide Buy, Sell, or Hold recommendations based on extensive research. This consensus number is ...and more »
05/30/16 10:03 PMNeuroderm Ltd (NDRM) Rating Reiterated by Roth Capital - Let Me Know About This - Neuroderm Ltd (NDRM) Rating Reiterated by Roth CapitalLet Me Know About ThisNeuroderm logo Neuroderm Ltd (NASDAQ:NDRM)'s stock had its “buy” rating reiterated by equities researchers at Roth Capital in a research report issued to clients and investors on Sunday. Several other analysts also recently commented on the company.NeuroDerm Ltd. (NDRM) Broker Price Targets For The Coming WeekShare Trading NewsWere Analysts Bearish Neuroderm Ltd (NASDAQ:NDRM) This Week?HNNall 3 news articles »
05/30/16 11:40 AMNeuroDerm Ltd. (NDRM) Broker Price Targets For The Coming Week - Share Trading News - NeuroDerm Ltd. (NDRM) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of NeuroDerm Ltd. (NDRM). The latest reports which are currently in issue on Monday 30th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts ...and more »
05/28/16 10:02 AMEarnings Review and Stock Rundown for NeuroDerm Ltd. (NASDAQ:NDRM) - Wall Street Hints and News - Earnings Review and Stock Rundown for NeuroDerm Ltd. (NASDAQ:NDRM)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting NeuroDerm Ltd. (NASDAQ:NDRM) to post ...and more »
05/28/16 10:02 AMNeuroderm Ltd (NASDAQ:NDRM) Could Be About To Enter The Multi-Billion Dollar Parkinson's Space - Market Exclusive - Market ExclusiveNeuroderm Ltd (NASDAQ:NDRM) Could Be About To Enter The Multi-Billion Dollar Parkinson's SpaceMarket ExclusiveNeuroderm Ltd (NASDAQ:NDRM) just gave us un update on its pipeline, and two elements in particular stood out as being potential drivers of near term volatility. The first, topline from a pharmacokinetic dose finding trial out of Europe – phase II – in ...
05/26/16 10:11 AMNeuroDerm reports 1Q loss - REHOVOT, Israel (AP) _ NeuroDerm Ltd. (NDRM) on Thursday reported a loss of $5.4 million in its first quarter. The Rehovot, Israel-based company said it had a loss of 25 cents per share. The results exceeded Wall Street expectations. The average estimate ...
05/05/16 09:14 AMNeuroDerm Announces 2016 Annual General Meeting of Shareholders - [GlobeNewswire] - REHOVOT, Israel, May 05, 2016-- NeuroDerm Ltd., a clinical-stage pharmaceutical company developing drugs for central nervous system diseases, today announced that it will hold its 2016 Annual General Meeting ...
04/22/16 09:47 AMNeuroDerm Reveals Removal Of Import Alert By FDA On Infusion Pumps -
04/22/16 08:31 AMNeuroDerm Announces Removal of FDA Import Alert of Infusion Pumps Used in ND0612 Clinical Trials - [GlobeNewswire] - REHOVOT, Israel, April 22, 2016-- NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system diseases, today announced that the Company has been informed by Canè ...
04/05/16 06:00 AMNeuroDerm Parkinson’s Disease Clinical Data Selected for Two Oral Presentations at the American Academy of Neurology 68th Annual Meeting - [GlobeNewswire] - -An Encore Presentation on ND0612 Will be Given at the Invited Science: Movement Disorders Session Following the Identification of ND0612 Stable Levodopa Plasma Levels as a Critical Advance in the Field ...
04/01/16 11:40 AMEdited Transcript of NDRM earnings conference call or presentation 31-Mar-16 12:30pm GMT -
03/31/16 06:07 AMQ4 2015 Neuroderm Ltd Earnings Release - Before Market Open -
03/31/16 06:00 AMNeuroDerm Announces Fourth Quarter and Full Year 2015 Financial Results and Provides a Corporate Update - [GlobeNewswire] - REHOVOT, Israel, March 31, 2016-- NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system diseases, today announced financial results for the fourth quarter ...

Social

About NeuroDerm

NeuroDerm logoNeuroDerm Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in developing treatments for central nervous system (CNS) disorders, primarily Parkinson's disease, as well as other CNS diseases. The Company is developing ND0612H for the treatment of patients suffering from severe Parkinson's disease; ND0612L for the treatment of patients at the moderate stage of Parkinson's disease that can no longer control motor complications with oral levodopa, and ND0680 for the treatment of a small subset of severe Parkinson's disease patients, whose symptoms have advanced to a severe stage, requiring even higher doses of LD/CD than ND0612H is designed to provide. The Company has also designed ND0701, an apomorphine-based product candidate that offers an alternative to the continuously administered apomorphine product, and ND0801, to treat cognition disorders associated with CNS diseases, such as ADD/ADHD, Alzheimer's disease and schizophrenia.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: NDRM
  • CUSIP:
Key Metrics:
  • Previous Close: $17.51
  • 50 Day Moving Average: $16.95
  • 200 Day Moving Average: $15.38
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $378.37M
  • Beta: 0.91
  • Current Year EPS Consensus Estimate: $-1.52 EPS
  • Next Year EPS Consensus Estimate: $-1.90 EPS
Additional Links:
NeuroDerm (NASDAQ:NDRM) Chart for Sunday, July, 24, 2016